In addition to the role of tumor neoantigen-specific CD8+ T cells in cancer elimination through MHC class I [57,58,59,60,61], enhanced antitumor activity requires activation of CD4+ T cells via MHC class II in response to immunotherapy [62]. The gene discussed is CD8A; the disease is neoplasm.